BLASUBCUTANEOUSSOLUTION2 Generics Approved
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
FIASP FLEXTOUCH (insulin aspart injection) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2017.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIASP FLEXTOUCH is a rapid-acting insulin analog (insulin aspart) administered via subcutaneous injection in a pre-filled pen device. It is indicated for diabetes management in patients requiring insulin therapy to control blood glucose levels. The formulation enhances the speed of insulin absorption compared to standard insulin aspart, enabling faster postprandial glucose control.
$106MPart D
PeakProduct is at peak lifecycle stage with $106M in Part D spending; stable commercial team focused on market maintenance and patient retention.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
$106M Medicare spend — this is a commercially significant brand
Worked on FIASP FLEXTOUCH at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.